Navigation Links
Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia
Date:10/16/2007

SAN FRANCISCO, Oct. 16 /PRNewswire/ -- Sugammadex -- the novel selective relaxant binding agent (SRBA) being developed by Organon -- demonstrated a faster recovery from profound neuromuscular blockade as compared to neostigmine in the Phase III pivotal Signal trial.(1) In a second trial, named Spectrum, faster recovery from profound neuromuscular blockade compared to spontaneous recovery was demonstrated.(2) The pivotal Signal trial results were presented today at the 2007 annual meeting of the American Society of Anesthesiologists (ASA) taking place in San Francisco from October 13-17. The Spectrum trial results were presented on October 14.

The Signal trial compared the efficacy and safety of sugammadex and neostigmine/glycopyrrolate for the reversal of profound rocuronium (Zemuron(R)/ Esmeron(R)/Eslax(R)) induced neuromuscular blockade. The Spectrum trial compared the efficacy and safety of sugammadex for reversal of profound rocuronium-induced neuromuscular blockade with that of spontaneous recovery from succinylcholine-induced blockade.

"The Signal trial results are clinically significant for anesthesiologists during neuromuscular blockade management, as with sugammadex they will be able to have control when using any depth of rocuronium-induced neuromuscular, and be able to reverse the blockade rapidly at any moment they want, which is not possible with current treatments," said Professor James E. Caldwell, University of California, San Francisco and one of the lead Signal trial investigators.

Reversal agents are used during general anesthesia to reverse the effects of muscle relaxants, also called neuromuscular blocking agents (NMBAs). Reversal of neuromuscular blockade enables spontaneous breathing to recommence earlier which helps to get patients out of the operating room quicker, freeing up capacity and personnel to help additional patients. Adequate reversal reduces the risk of residual paralysis, which may cause a number of serio
'/>"/>

SOURCE Organon
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
2. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
3. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
4. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
5. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
6. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
7. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. Two Phase III clinical trials on corifollitropin alfa (Org 36286) reach randomization target
10. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
11. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... MILFORD, Pa. , Sept. 17, 2014  Fortune ... has officially changed its name to Manzo Pharmaceuticals, Inc. ... change to take effect today, September 17, 2014. Also ... split. The approval is a pivotal event ... Manzo . Mr. Manzo explained, "We could not proceed ...
(Date:9/17/2014)... -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), a ... an unsolicited, non-binding proposal from Endo International plc (NASDAQ: ... outstanding shares of Auxilium common stock at a price ... subject to due diligence, financing and other conditions. A ... from Endo on Friday evening is reproduced below. ...
(Date:9/17/2014)... -- Mindray (NYSE: MR)announced its new generation DC-70 ultrasound ... been showcased for the first time at ISUOG in ... is scheduled for availability in the U.S. market in ... efficient workhorse in the mid-range segment, the DC-70 combines ... user experience including a gesture-sensitive touch screen, delivering accurate ...
Breaking Medicine Technology:Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7Quality Exams at Your Fingertips 2
... July 29 Micromet, Inc.,(Nasdaq: MITI ), ... treatment of cancer, inflammation and autoimmune,diseases, today announced ... audio,webcast on Thursday, August 7, 2008, at 9:00 ... discuss its second quarter 2008 financial,results. Micromet anticipates ...
... July 28 BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ... study of intravenous (i.v.) peramivir administered via a ... treatment of seasonal,influenza. The trial, conducted by BioCryst,s ... primary endpoint of improvement in the median time ...
Cached Medicine Technology:Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 2BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 4BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 5
(Date:9/17/2014)... By Steven Reinberg ... -- On the same day that President Barack Obama announced ... Africa,s Ebola crisis, the World Health Organization warned Tuesday that ... infections could start doubling every three weeks. Obama said ... offer medical and logistical support to beleaguered health care facilities ...
(Date:9/17/2014)... severe maternal morbidity amongst women in Australia is ... study published today (17 September) in BJOG: ... , Australians generally enjoy high standards of living; ... exist, in particular between indigenous and non indigenous ... the independent impact of socioeconomic position on severe ...
(Date:9/17/2014)... of a perfectly poured glass of wine leads to an ... Denmark, have now developed a nanosensor that can mimic what ... measures how you experience the sensation of dryness in the ... they need to control a number of processes to bring ... in the wine bottle. An important part of the taste ...
(Date:9/17/2014)... 17, 2014 MarijuanaStock.net, a cannabis ... recently launched a “Video” section that contains important ... in the marijuana industry made available in video ... visitor is given access to numerous interviews, news ... businesses and the issues they face. , ...
(Date:9/17/2014)... Fresh off their High Times Cannabis ... support of The Silver Tour, an educational non-profit effort ... benefits of medical marijuana. , Florida Buds, a Florida ... marijuana dispensary and treatment center, donated $1,000.00 to ... launch a statewide radio campaign in advance of Election ...
Breaking Medicine News(10 mins):Health News:Obama Steps Up Aid to Fight Ebola in West Africa 2Health News:Obama Steps Up Aid to Fight Ebola in West Africa 3Health News:New study examines the impact of socioeconomic position and maternal morbidity in Australia 2Health News:New study examines the impact of socioeconomic position and maternal morbidity in Australia 3Health News:Nanoscience makes your wine better 2Health News:Nanoscience makes your wine better 3Health News:MarijuanaStock.net Adds Business News Video Section to Their Website 2Health News:Florida Buds Supports Silver Tour 2
... Therapeutics Inc. (Nasdaq CM: CRTX), a specialty pharmaceutical company ... for the respiratory and related markets, today announced that ... Vice President, General Counsel and Secretary. In this ... team and manage its legal function and corporate governance ...
... ... Drug Administration approved the use of silicone implants for breast augmentation procedures in women over ... decision capped a controversy that spanned more than a decade, and one plastic surgeon ... , ...
... , ... 1-3 December at Olympia Grand Hall, London, ... across Mainland Europe with two brand new features -- The French ... France, and The European Librarians’ Theatre which hosts sessions on topical ...
... CHARLOTTE, N.C., Nov. 12 Even with the economy still ... - and in quite a creative way. , Southeast Pain ... Dec. 3 performance of "Grease" at Ovens Auditorium and giving ... , "We are committed to supporting our patients in ...
... INDIANAPOLIS, Nov. 12 Centerplate, the hospitality ... sports stadiums, announced today with the Capital Improvement ... investigation of Lucas Oil Stadium to immediately address ... facility operates as a model of operational excellence ...
... are highlights from the November issue of Mayo ... as often as you wish. Mayo Clinic ... Reprinting is allowed for a fee. Include the following ... www.bookstore.mayoclinic.com or call toll-free for subscription ...
Cached Medicine News:Health News:Cornerstone Therapeutics Appoints General Counsel 2Health News:Cornerstone Therapeutics Appoints General Counsel 3Health News:Valencia, California, Plastic Surgeon Weighs in on Silicone Breast Implants – 3 Years After FDA Approval 2Health News:Valencia, California, Plastic Surgeon Weighs in on Silicone Breast Implants – 3 Years After FDA Approval 3Health News:Valencia, California, Plastic Surgeon Weighs in on Silicone Breast Implants – 3 Years After FDA Approval 4Health News:Online Information 2009 Exhibition Focuses on Mainland Europe 2Health News:Online Information 2009 Exhibition Focuses on Mainland Europe 3Health News:Southeast Pain Care Provides Relief and Gives Back - Creatively 2Health News:Centerplate and the Capital Improvement Board Investigating Food Safety Violations at Lucas Oil Stadium to Ensure Highest Standards Achieved and Operational Excellence 2Health News:November 2009 Mayo Clinic Women's HealthSource Highlights Reducing Cancer Risk, Tips to Reduce Flatulence and Eating Nuts for Heart Health 2Health News:November 2009 Mayo Clinic Women's HealthSource Highlights Reducing Cancer Risk, Tips to Reduce Flatulence and Eating Nuts for Heart Health 3Health News:November 2009 Mayo Clinic Women's HealthSource Highlights Reducing Cancer Risk, Tips to Reduce Flatulence and Eating Nuts for Heart Health 4Health News:November 2009 Mayo Clinic Women's HealthSource Highlights Reducing Cancer Risk, Tips to Reduce Flatulence and Eating Nuts for Heart Health 5
... Gemini is the newest addition to Laserscopes ... distinct wavelengths to choose from, 1064nm Nd:YAG ... in an exploding non-invasive aesthetic laser market ... and effectiveness while maintaining the safety and ...
... Surgical Laser System is designed for ... high-power, dual-wavelength system designed for urology, ... surgery, neurosurgery, pulmonary surgery and gastroenterology ... vaporizes and coagulates tissue with minimal ...
... biolitecs Ceralas D 980 nm diode laser ... bloodless field for most surgical procedures. ... cuts optically without collateral tissue damage ... coagulates blood instantly and seals small blood ...
... is a monoclonal antibody based ... confirmatory identification of Neisseria gonorrhoeae. ... isolated, viable or fresh cultures. ... two minute rotation, a positive ...
Medicine Products: